GAM
ANIP icon

Goldentree Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Goldentree Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-667,981
Closed -$51.3M – 33
2026
Q1 		$51.3M Buy
+667,981
New +$52.1M 3.04% 12

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldentree Asset Management's ANIP Position: Q2 2026 in Review

Goldentree Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2026, closing a stake of 667,981 shares — an estimated $51.3M sold.

Goldentree Asset Management first reported a position in ANIP in Q1 2026 and held it in 1 quarter. The position peaked at $51.3M in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Goldentree Asset Management reported no remaining ANI Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Goldentree Asset Management sold 667,981 ANI Pharmaceuticals shares in Q2 2026, an estimated $51.3M.
  • Goldentree Asset Management first reported a position in ANI Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Goldentree Asset Management's ANI Pharmaceuticals position peaked at $51.3M in Q1 2026.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Goldentree Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.